A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma
The Maximum Tolerated Dose of the combination was determined and the Phase I terminated.
Then, Phase II study started.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Maximum Tolerated Dose (MTD) of combination of TLC D-99 and Ifosfamide
Definition of TDL
Yes
Armando Santoro, MD
Principal Investigator
Istituto Clinico Humanitas
Italy: Ministry of Health
ONC-2005-001
NCT00289809
September 2006
December 2009
Name | Location |
---|